| VABP
Zerbaxa vs Recarbrio
Side-by-side clinical, coverage, and cost comparison for vabp.Deep comparison between: Zerbaxa vs Recarbrio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRecarbrio has a higher rate of injection site reactions vs Zerbaxa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Recarbrio but not Zerbaxa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zerbaxa
Recarbrio
At A Glance
IV infusion
Every 8 hours
Cephalosporin/beta-lactamase inhibitor
IV infusion
Every 6 hours
Carbapenem + beta-lactamase inhibitor
Indications
- Peritonitis
- Urinary tract infection
- Pyelonephritis
- Hospital acquired pneumonia
- VABP
- Hospital acquired bacterial pneumonia
- VABP
- Complicated urinary tract infection
- Pyelonephritis
- Complicated intra-abdominal infection
Dosing
Peritonitis 1.5 g IV every 8 hours over 1 hour for 4 to 14 days, used in conjunction with metronidazole 500 mg IV every 8 hours; pediatric patients: 30 mg/kg up to 1.5 g every 8 hours for 5 to 14 days.
Urinary tract infection, Pyelonephritis 1.5 g IV every 8 hours over 1 hour for 7 days; pediatric patients: 30 mg/kg up to 1.5 g every 8 hours for 7 to 14 days.
Hospital acquired pneumonia, VABP 3 g IV every 8 hours over 1 hour for 8 to 14 days in adult patients 18 years and older.
Hospital acquired bacterial pneumonia, VABP, Complicated urinary tract infection, Pyelonephritis, Complicated intra-abdominal infection Adults with CLcr >=90 mL/min: 1.25 g (imipenem 500 mg/cilastatin 500 mg/relebactam 250 mg) IV infusion over 30 minutes every 6 hours for 4-14 days; dose reduction required for CLcr <90 mL/min; pediatric patients (>=2 kg): weight- and age-based dosing of 37.5 mg/kg every 6-8 hours IV.
Contraindications
- Known serious hypersensitivity to components of ZERBAXA (ceftolozane and tazobactam), piperacillin/tazobactam, or other members of the beta-lactam class
- Severe hypersensitivity (e.g., anaphylaxis) to any component of RECARBRIO
Adverse Reactions
Most common (>=5%) Nausea, diarrhea, headache, pyrexia
Serious Hypersensitivity reactions, Clostridioides difficile-associated diarrhea, intracranial hemorrhage, renal impairment/renal failure, hepatic transaminase increased
Most common (>=4%) Anemia, diarrhea, AST increased, ALT increased, hypokalemia, hyponatremia, constipation, pyrexia, rash
Serious Hypersensitivity reactions, seizures and other CNS adverse reactions, Clostridioides difficile-associated diarrhea
Pharmacology
Ceftolozane is a cephalosporin antibacterial that inhibits bacterial cell wall biosynthesis by binding to penicillin-binding proteins (PBPs); tazobactam is an irreversible beta-lactamase inhibitor that extends ceftolozane activity against beta-lactamase-producing organisms.
RECARBRIO combines imipenem (a carbapenem that inhibits bacterial cell wall synthesis by binding PBP 2 and PBP 1B), cilastatin (a renal dehydropeptidase inhibitor that prevents renal metabolism of imipenem), and relebactam (a diazabicyclooctane beta-lactamase inhibitor that protects imipenem from degradation by serine beta-lactamases including KPC, AmpC-type PDC, SHV, TEM, and CTX-M enzymes).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zerbaxa
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (0/12)
Recarbrio
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
Zerbaxa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Recarbrio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Zerbaxa
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Recarbrio
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Zerbaxa.
No savings programs available for Recarbrio.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZerbaxaView full Zerbaxa profile
RecarbrioView full Recarbrio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.